Repligen Corp (RGEN) 10-K Annual Report March 2015

Repligen Corporation (NASDAQ:RGEN) today reported financial results for the fourth quarter and year ended December 31, 2014. Below are the Company’s performance highlights for these periods, followed by financial guidance for the year 2015 and access information for today’s webcast and conference call.

Walter C. Herlihy, Ph.D., President and Chief Executive Officer said, “2014 was an outstanding year for Repligen. We started the year with a focus on accelerating growth and expanding margins in our core business, while investing in our commercial organization and pursuing bioprocessing acquisition opportunities. We executed on all fronts, delivering 27% product sales growth and a 30% increase in gross profit bolstered by our acquisition of the ATF System and the launch of OPUS^® 45, a well-received line extension. Our success in 2014 provides a foundation for continued growth in 2015 and beyond.”

Business Highlights of 2014

•

In June, we acquired the business of Refine Technology and its market-leading ATF System used in the fermentation step of biomanufacturing. During the fourth quarter, the ATF business was consolidated into our Waltham, Massachusetts site as we completed the construction of our state-of-the-art ATF manufacturing area that became operational during the first quarter of 2015. ATF System sales over the seven months were $6.8 million, which was well ahead of our initial expectations and met the 2014 contingent consideration milestone defined in the Refine Asset Purchase Agreement. Based on achieving the 2014 milestone and the increased probability of achieving the 2015 sales milestone, we accrued $2.0 million in contingent consideration in the fourth quarter.

•

In March, we formally launched our OPUS^® 45 cm diameter chromatography columns which have the largest capacity currently available on the market. Adoption of OPUS 45 was very strong, contributing to OPUS growth of over 100% for the full year. OPUS columns are delivered pre-packed to customers with their choice of media used to purify monoclonal antibodies and other biologic drugs.

- more -

The following information was filed by Repligen Corp (RGEN) on Friday, March 13, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/730272/000119312515095569/d854858d10k.htm

View differences made from one year to another to evaluate Repligen Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Repligen Corp.

Continue

Assess how Repligen Corp's management team is paid from their Annual Proxy

Repligen Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Repligen Corp provided additional information to their SEC Filing as exhibits

Exhibit 10.16: Material Contract

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: RGEN
CIK: 730272
Form Type: 10-K Annual Report
Accession Number: 0001193125-15-095569
Submitted to the SEC: Tue Mar 17 2015 5:19:09 PM EST
Accepted by the SEC: Tue Mar 17 2015
Period: Wednesday, December 31, 2014
Industry: Biological Products No Disgnostic Substances